Robert M. Califf

Adjunct Professor of Medicine
Donald F. Fortin, M.D. Distinguished Professor of Cardiology, in the School of Medicine
Member of the Duke Clinical Research Institute
Campus mail 100 Trent Drive, Suite401, Davison Building, Durham, NC 27710
Phone (919) 668-9222
Email address robert.califf@duke.edu

Robert Califf, MD MACC, is the Donald F. Fortin, MD, Professor of Cardiology. He is also Professor of Medicine in the Division of Cardiology and remains a practicing cardiologist. Dr. Califf was the Commissioner of Food and Drugs in 2016-2017 and  Deputy Commissioner for Medical Products and Tobacco from February 2015 until his appointment as Commissioner in February 2016. Prior to joining the FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.

Dr. Califf is a Member of the National Academy of Medicine (formerly known as the Institute of Medicine (IOM)) in 2016, one of the highest honors in the fields of health and medicine. Dr. Califf has served on numerous IOM committees, and he has served as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board's Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging.

He has led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke's Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory coordinating center and co-PI of the Patient Centered Outcomes Research Institute Network.

Publications

Jones, William Schuyler, Anne S. Hellkamp, Jonathan Halperin, Jonathan P. Piccini, Gunter Breithardt, Daniel E. Singer, Keith A. A. Fox, et al. “Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.” Eur Heart J 35, no. 4 (January 2014): 242–49. https://doi.org/10.1093/eurheartj/eht492.

PMID
24302273
Full Text

Mahaffey, Kenneth W., Susanna R. Stevens, Harvey D. White, Christopher C. Nessel, Shaun G. Goodman, Jonathan P. Piccini, Manesh R. Patel, et al. “Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.” Eur Heart J 35, no. 4 (January 2014): 233–41. https://doi.org/10.1093/eurheartj/eht428.

PMID
24132190
Full Text

Holman, R. R., H. Sourij, and R. M. Califf. “Erratum: Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes (Lancet (2014) 383 (2008-17)).” The Lancet 383, no. 9936 (January 1, 2014): 2212. https://doi.org/10.1016/S0140-6736(14)61084-9.

Full Text

Fleurence, R. L., L. H. Curtis, R. M. Califf, R. Platt, J. V. Selby, and J. S. Brown. “Launching PCORnet, a national patient-centered clinical research network.” Journal of the American Medical Informatics Association 21, no. 4 (January 1, 2014): 578–82. https://doi.org/10.1136/amiajnl-2014-002747.

Full Text

Vo-Dinh, T., A. Mahadevan-Jansen, and W. S. Grundfest. “Introduction.” Progress in Biomedical Optics and Imaging  Proceedings of Spie 8935 (January 1, 2014).

Scholars@Duke

Piccini, J. P., A. S. Hellkamp, Y. Lokhnygina, M. R. Patel, F. E. Harrell, D. E. Singer, R. C. Becker, et al. “Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: Results from the ROCKET AF trial.” In Journal of the American Heart Association, Vol. 3, 2014. https://doi.org/10.1161/JAHA.113.000521.

Full Text

Kimmel, Stephen E., Benjamin French, Scott E. Kasner, Julie A. Johnson, Jeffrey L. Anderson, Brian F. Gage, Yves D. Rosenberg, et al. “A pharmacogenetic versus a clinical algorithm for warfarin dosing.” N Engl J Med 369, no. 24 (December 12, 2013): 2283–93. https://doi.org/10.1056/NEJMoa1310669.

PMID
24251361
Full Text

Shen, Lan, Bimal R. Shah, Eric M. Reyes, Laine Thomas, Daniel Wojdyla, Peter Diem, Lawrence A. Leiter, et al. “Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.” Bmj 347 (December 9, 2013): f6745. https://doi.org/10.1136/bmj.f6745.

PMID
24322398
Full Text

Pages